Towards a new type-of HMG-COA reductase inhibitor
Martine Barth, F. D. BELLAMY, Patrice P. Renaut et al. · Tetrahedron · 1990
Cited by 21 works. doi:10.1016/s0040-4020(01)87862-5
Authors
References
- The Low-Density Lipoprotein Pathway and its Relation to Atherosclerosis
- ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogensis produced by Penicillium citrinum.
- New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase.
- Asymmetric carbon-carbon bond formation via .beta.-allyldiisopinocampheylborane. Simple synthesis of secondary homoallylic alcohols with excellent enantiomeric purities
- Compactin (ML-236B) and related compounds as potential cholesterol-lowering agents that inhibit HMG-CoA reductase
- Regulation of 3-hydroxy-3-methylglutarate and mevalonate biosynthesis by rat liver homogenates. Effects of fasting, cholesterol feeding, and triton administration
- Structure and synthesis of dihydroxypentyluracil from bacteriophage SP-15 deoxyribonucleic acid
- A Probable Intermediate in the Enzymic Reduction of 3-Hydroxy-3-methylglutaryl Coenzyme A
- Synthetic and biological studies of compactin and related compounds. 4. Total synthesis of (+)-compactin
- Stereocontrolled synthesis of the spiro ketal unit of avermectin B1a aglycon